MedTrace Logo

Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)

NCT03737838 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2024-05-07

No results posted yet for this study

Summary

The purpose of this study is to perform ultra-high density mapping of the left atrium (a chamber of the heart) using the the Rhythmia Mapping System and to determine whether additional ablation in areas of wavefront discontinuities identified by the map will reduce the likelihood of both atrial fibrillation and atrial flutter.

Conditions

Interventions

DEVICE

Atrial fibrillation ablation

High density mapping of left atrium using Rhythmia mapping system to identify gaps in conduction and wavefront discontinuities (deceleration zones)

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Roderick Tung · University of Chicago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2021-02-24
Completion
2021-02-24
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03737838 on ClinicalTrials.gov